Alvotech Reveals Positive Data For Stelara Rival

Results For AVT04 Ustekinumab Biosimilar Come Ahead Of Oaktree SPAC Merger Vote

 
• By Dave Wallace

Alvotech has reported positive results from a study for its AVT04 proposed biosimilar ustekinumab rival to Stelara. The news comes ahead of a key vote on Alvotech’s SPAC merger with Oaktree Capital Management that will take the company public.

$9bn nine billion dollars yellow icon
Stelara represents a $9bn target for Alvotech • Source: Shutterstock

More from Biosimilars

More from Products